semaglutide
-
healthNHS to Offer Semaglutide to 1.2 Million Cardiovascular Patients
NICE approves Wegovy for high-risk patients following major clinical trials showing 20% reduction in cardiovascular events.
-
healthGLP-1 Drugs Linked to Improved Mental Health in New Study
A large Swedish study finds semaglutide and liraglutide tied to lower risks of worsening anxiety, depression, and substance use disorders.
-
healthWeight-Loss Drug Semaglutide Linked to Lower Mental Health Risks
New study shows semaglutide significantly reduces risks of depression, anxiety, and self-harm in patients with obesity or diabetes.
-
healthGLP-1 Drugs Linked to Lower Risk of Worsening Anxiety and Depression
Semaglutide and liraglutide show significant mental health benefits in patients with anxiety or depression, per large-scale Swedish study.
-
healthGLP-1 Users Regain Minimal Weight After Stopping, Real-World Study Finds
A Cleveland Clinic study shows most patients regain only 0.5% of lost weight a year after stopping Ozempic or similar GLP-1 drugs.
-
healthIndia's Generic Semaglutide Surge Could Reshape Global Obesity Treatment
With Novo Nordisk's semaglutide patent expiring in India, domestic manufacturers are preparing dozens of affordable generics, potentially slashing costs and expanding access to GLP-1 weight-loss drugs worldwide.
-
healthOzempic Users Keep Off 25% of Lost Weight After Stopping
New study reveals weight regain patterns after discontinuing GLP-1 drugs like Ozempic and Wegovy, raising concerns over muscle loss and long-term health.
-
healthFDA Cites Novo Nordisk for Failing to Report Patient Deaths Linked to GLP-1 Drugs
The FDA issued a warning letter accusing Novo Nordisk of systemic failures in reporting serious side effects-including deaths-of patients using Ozempic and Wegovy.